Ganetespib - Aldeyra Therapeutics

Drug Profile

Ganetespib - Aldeyra Therapeutics

Alternative Names: ADX 1612; SARC 023; STA-9090

Latest Information Update: 24 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Synta Pharmaceuticals
  • Developer Aldeyra Therapeutics; Cancer Research UK; Cardiff University; Emory University; Innsbruck Medical University; Madrigal Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; Multiple Myeloma Research Consortium; Synta Pharmaceuticals
  • Class Antineoplastics; Eye disorder therapies; Indoles; Resorcinols; Small molecules; Triazoles
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Ovarian cancer
  • Phase I/II Mesothelioma
  • Phase I Lymphoproliferative disorders
  • Discontinued Acute myeloid leukaemia; Breast cancer; Chronic myeloid leukaemia; Colorectal cancer; Fallopian tube cancer; Gastric cancer; Gastrointestinal stromal tumours; Head and neck cancer; Liver cancer; Malignant melanoma; Multiple myeloma; Myelodysplastic syndromes; Neuroendocrine tumours; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Peritoneal cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Rectal cancer; Sarcoma; Small cell lung cancer; Uveal melanoma

Most Recent Events

  • 16 Oct 2018 Katholieke Universiteit Leuven initiates enrolment in a phase II trial for Ovarian cancer, Fallopian tube cancer and Peritoneal cancer (Combination therapy, Second line therapy or greater) in Belgium (EudraCT2017-004058-40)
  • 10 Oct 2018 Aldeyra Therapeutics plans a phase II trial for Mesothelioma in 2019 (Aldeyra Therapeutics pipeline, October 2018)
  • 25 Sep 2018 Positive top-line efficacy and adverse events data from the phase I/II MESO-2 trial in Mesothelioma released by Aldeyra Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top